THU0095 Clinical Characteristics of Elderly Onset Rheumatoid Arthritis (EORA) Compared To Young Onset Rheumatoid Arthritis (YORA) in Young and Old

2016 ◽  
Vol 75 (Suppl 2) ◽  
pp. 213.2-213
Author(s):  
I. Yoshii ◽  
T. Chijiwa
2010 ◽  
Vol 14 (4) ◽  
pp. 227-233 ◽  
Author(s):  
Hyun Ok Kim ◽  
Ho Sung Yoon ◽  
Seung Ki Kwok ◽  
Ji Hyeon Ju ◽  
Kyung Su Park ◽  
...  

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 974.1-975
Author(s):  
P. Kozhevnikova ◽  
I. Dydykina ◽  
P. Kovalenko ◽  
A. Lila

Background:Rheumatoid arthritis (RA) is a chronic autoimmune disease, characterized by erosive arthritis and systemic organ involvement. Chronic inflammation, long RA disease duration, decreased physical activity, immobilization, glucocorticoids use lead to local (periarticular osteoporosis) and generalized loss of bone tissue, decrease in bone mineral density, contravention of microarchitectonics and increased risk of fragility (low-energy) fractures. The structure and density of bone tissue at elderly onset RA, in addition to the above factors, are affected by comorbid diseases, sex steroids level decrease and molecular changes in bone tissue, specifically attributed to aging, followed by increased bone resorption. Fractures reduce the quality of life, have a negative impact on the course of the underlying and concomitant diseases.Objectives:Сompare frequency of fragility fracture in patients with elderly onset rheumatoid arthritis and young onset rheumatoid arthritis.Methods:We included 474 patients with RA diagnosed at 25– 78 years old and fulfilled the American College of Rheumatology (formerly American Rheumatism Association) classification criteria for RA revised in 1987. The patients were divided into two groups depending on age at the RA-onset: The first group (group I) included 217 patients with young onset RA (at 25 to 44 years), second group (group II) included 66 patients with elderly onset RA (aged ≥60 years). The distribution of patients into groups was consistent with the age classification of the World Health Organization. In total, it was selected 283 RA patients. The mean age in group I was 50.4 years, in group II - 71.2 years. The mean age at the onset of RA in group I was 35.0 years, in group II - 66.2 years.; RA duration was 14.4 years and 4.6 years, respectively. Long-term history of glucocorticoids use (for more than 3 months) was observed in 50% of patients in group I, and in 42% of patients in group II.Results:40 (18%) patients in group I and 17 (26%) patients in group II had fragility fractures. Among patients with fragility fracture, 23 (57,5%) patients in group I and 6 (35%) patients in group II received glucocorticoid therapy for more than 3 months. Two or more fractures in history had 16 (40%) in group I, and 3 (18%) in group II.Conclusion:The frequency of fragility fracture in the study groups was comparable (p> 0.05), despite the age of patients. But, the frequency of refractures was higher in patients with RA-onset at young age, which, apparently, is a consequence of long RA disease duration and use of glucocorticoids.Disclosure of Interests:None declared


2021 ◽  
Vol 10 (6) ◽  
pp. 1204
Author(s):  
Bożena Targońska-Stępniak ◽  
Krzysztof Grzechnik ◽  
Katarzyna Kolarz ◽  
Danuta Gągoł ◽  
Maria Majdan

Background: Rheumatoid arthritis (RA) occurs more often in elderly individuals. Elderly onset RA (EORA) (onset > 60 years) encompasses a specific subset of patients if compared with young onset RA (YORA) (onset at a younger age). There is a need to define reliable, simple markers to properly assess the inflammatory activity of RA. Hematological markers of systemic inflammation (Platelet-To-Lymphocyte (PLR) and Neutrophil-To-Lymphocyte (NLR) ratios) are novel measures of the inflammatory response. The goal of the study was to analyze the course of EORA vs. YORA patients and to assess associations between systemic and clinical disease activity markers, including PLR and NLR, in different subsets of patients. PLR and NLR have not previously been assessed in EORA and YORA. Methods: The study group consisted of 113 consecutive patients (63 EORA and 50 YORA). The following assessments were performed: joint counts, Disease Activity Score (DAS28), complete blood cell counts, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Results: EORA was characterized by significantly higher disease activity markers (conventional inflammatory and clinical), a lower rate of remission or low disease activity, and less frequent use of biological drugs and glucocorticoids. The NLR and PLR were positively correlated with disease activity markers. The PLR was significantly lower in EORA compared with in YORA. Conclusion: EORA and YORA patients differed significantly. In EORA, conventional disease activity markers were higher, the PLR was significantly lower.


2021 ◽  
pp. jrheum.201135
Author(s):  
Sae Ochi ◽  
Fumitaka Mizoguchi ◽  
Kazuhisa Nakano ◽  
Yoshiya Tanaka

Objective Increasing numbers of patients are developing rheumatoid arthritis (RA) at an older age, and optimal treatment of elderly-onset RA (EORA) patients is attracting greater attention. This study aimed to analyze the efficacy and safety of biological/targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) in EORA and non-EORA elderly patients. Methods A cohort of RA patients treated with b/tsDMARDs were retrospectively analyzed. Among patients who were ≥60 years old, those who developed RA after age 60 years were categorized as EORA, while others were categorized as non-EORA elderly. Disease activity were compared between the EORA and non-EORA elderly groups. Results In total, 1,040 patients were categorized as EORA and 710 as non-EORA elderly. There were not significant differences in characteristics at baseline between the two groups. The proportion of patients with low and high disease activity was comparable at week 2, 22 and 54 between in the EORA and the non-EORA elderly group. There was not significant difference in reasons of the discontinuation of b/tsDMARDs between the two groups. Elderly onset did not affect changes in CDAI and HAQ-DI as well as reasons of the discontinuation between the two groups. The trajectory analysis on CDAI-responses to b/tsDMARDs for 54 weeks identified three response patterns. The proportions of patients categorized into each group and CDAI-response trajectories to b/tsDMARDs were very similar between EORA and non-EORA elderly patients. Conclusion CDAI response patterns to b/tsDMARDs and hazard ratio of adverse events were similar between EORA and non-EORA elderly patients.


2010 ◽  
Vol 77 (4) ◽  
pp. 290-296 ◽  
Author(s):  
Martin Soubrier ◽  
Sylvain Mathieu ◽  
Sarah Payet ◽  
Jean-Jacques Dubost ◽  
Jean-Michel Ristori

Author(s):  
Melania Martínez-Morillo ◽  
águeda Prior-Español ◽  
Anahy Brandy-Garcia ◽  
Susana Holgado ◽  
María Aparicio-Espinar ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document